US equities |
NVDA $239.24 ▲+0.14% MU $1,048.71 ▼-1.43% SPCX $172.91 ▲+1.06% MRVL $285.97 ▲+5.43% AMD $651.53 ▲+3.13% INTC $113.30 ▼-2.49% AVGO $377.69 ▲+4.19% SNDK $1,655.61 ▼-2.85%
FinancialContent

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

61.28 -1.07 (-1.72%)
Delayed Quote Updated: 3:40 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? ↗
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT).... 
Via Benzinga
News headline image
A Look Ahead: Arrowhead Pharma's Earnings Forecast ↗
 
Via Benzinga
News headline image
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta ↗
The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets. 
Via Investor's Business Daily
News headline image
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 26, 2024 ↗
 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
From Arrowhead Pharmaceuticals, Inc
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q3 2024 ↗
ARWR stock results show that Arrowhead Pharma missed analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
Topics Stocks
News headline image
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
News headline image
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 ↗
Low priced stocks to buy for growth provide great value to investors in the $20 range and are expected to pop before 2025. 
Via InvestorPlace
News headline image
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >